Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMED Amedisys	$98.08 +0.4%	$95.03	$82.15 ▼ $98.95	$3.20B	0.94	419,342 shs	287,043 shs
ENOV Enovis	$32.17 +0.7%	$33.06	$28.83 ▼ $49.83	$1.83B	1.71	846,546 shs	1.11 million shs
GKOS Glaukos	$99.42 -0.8%	$94.31	$77.10 ▼ $163.71	$5.73B	0.8	736,257 shs	404,092 shs
PINC Premier	$21.85 +0.5%	$22.05	$17.23 ▼ $23.56	$1.79B	0.57	1.22 million shs	1.24 million shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMED Amedisys	-0.19%	+0.14%	+4.52%	+5.65%	+6.55%
ENOV Enovis	+6.53%	+3.41%	+1.12%	-18.37%	-29.03%
GKOS Glaukos	+3.51%	+0.18%	+4.13%	-2.97%	-10.48%
PINC Premier	-0.64%	-2.25%	-5.68%	+14.35%	+17.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMED Amedisys	3.3216 of 5 stars	1.1	3.0	0.0	5.0	2.8	1.7	1.3
ENOV Enovis	2.7327 of 5 stars	3.4	2.0	0.0	0.0	1.3	1.7	1.9
GKOS Glaukos	4.5243 of 5 stars	4.4	2.0	0.0	4.4	2.1	2.5	0.6
PINC Premier	2.2587 of 5 stars	1.0	3.0	2.5	0.0	2.5	2.5	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMED Amedisys	2.20	Hold	$100.75	2.72% Upside
ENOV Enovis	2.80	Moderate Buy	$58.00	80.29% Upside
GKOS Glaukos	2.75	Moderate Buy	$134.67	35.45% Upside
PINC Premier	2.00	Hold	$22.20	1.60% Upside

Current Analyst Ratings Breakdown

Latest PINC, ENOV, GKOS, and AMED Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/21/2025	PINC Premier	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$19.00 ➝ $24.00
5/15/2025	PINC Premier	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$19.00 ➝ $22.00
5/14/2025	ENOV Enovis	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$75.00 ➝ $70.00
5/9/2025	ENOV Enovis	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$62.00 ➝ $55.00
5/9/2025	ENOV Enovis	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$64.00 ➝ $57.00
5/8/2025	PINC Premier	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$19.00 ➝ $22.00
5/6/2025	GKOS Glaukos	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$110.00 ➝ $72.00
5/2/2025	GKOS Glaukos	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$140.00 ➝ $115.00
5/1/2025	GKOS Glaukos	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$140.00 ➝ $135.00
5/1/2025	GKOS Glaukos	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$140.00 ➝ $115.00
5/1/2025	GKOS Glaukos	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$176.00 ➝ $115.00

(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMED Amedisys	$2.35B	1.37	$6.26 per share	15.67	$36.03 per share	2.72
ENOV Enovis	$2.11B	0.87	$19.38 per share	1.66	$45.10 per share	0.71
GKOS Glaukos	$383.48M	14.81	N/A	N/A	$13.91 per share	7.15
PINC Premier	$1.35B	1.34	$3.65 per share	5.98	$18.68 per share	1.17

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMED Amedisys	$43.23M	$2.71	36.19	20.26	1.33	3.79%	12.52%	7.01%	7/23/2025 (Estimated)
ENOV Enovis	-$825.49M	-$13.95	N/A	10.08	N/A	-37.65%	5.99%	3.44%	8/6/2025 (Estimated)
GKOS Glaukos	-$146.37M	-$2.37	N/A	N/A	N/A	-31.40%	-10.66%	-8.06%	7/30/2025 (Estimated)
PINC Premier	$119.54M	$0.57	38.33	16.43	N/A	5.68%	8.79%	4.86%	8/19/2025 (Estimated)

Latest PINC, ENOV, GKOS, and AMED Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/23/2025	Q2 2025	AMED Amedisys	$1.39	N/A	N/A	N/A	$614.61 million	N/A
5/8/2025	Q1 2025	ENOV Enovis	$0.74	$0.81	+$0.07	-$0.98	$558.80 million	$558.83 million
4/30/2025	Q1 2025	GKOS Glaukos	-$0.33	-$0.22	+$0.11	-$0.32	$102.78 million	$106.66 million
4/23/2025	Q1 2025	AMED Amedisys	$1.13	$1.25	+$0.12	$1.84	$597.43 million	$594.78 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMED Amedisys	N/A	N/A	N/A	N/A	N/A
ENOV Enovis	N/A	N/A	N/A	N/A	N/A
GKOS Glaukos	N/A	N/A	N/A	N/A	N/A
PINC Premier	$0.84	3.84%	N/A	147.37%	N/A

Latest PINC, ENOV, GKOS, and AMED Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/24/2025	PINC Premier	quarterly	$0.21	4.2%	5/30/2025	6/1/2025	6/15/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMED Amedisys	0.27	1.29	1.29
ENOV Enovis	0.52	2.55	1.32
GKOS Glaukos	0.09	6.49	5.62
PINC Premier	N/A	0.65	0.65

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMED Amedisys	94.36%
ENOV Enovis	98.45%
GKOS Glaukos	99.04%
PINC Premier	74.41%

Insider Ownership

Company	Insider Ownership
AMED Amedisys	2.10%
ENOV Enovis	2.70%
GKOS Glaukos	5.80%
PINC Premier	0.96%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMED Amedisys	19,000	32.82 million	32.13 million	Optionable
ENOV Enovis	7,367	57.12 million	55.58 million	Optionable
GKOS Glaukos	780	57.14 million	53.83 million	Optionable
PINC Premier	2,900	82.34 million	81.55 million	Optionable

PINC, ENOV, GKOS, and AMED Headlines

Recent News About These Companies

Aero Energy Completes Acquisition of Kraken Energy to Create a Premier North American Uranium Developer

June 23 at 8:02 AM | newsfilecorp.comN

GAMMA Investing LLC Raises Holdings in Premier, Inc. (NASDAQ:PINC)

June 20, 2025 | marketbeat.com

Exchange Traded Concepts LLC Acquires 16,663 Shares of Premier, Inc. (NASDAQ:PINC)

June 18, 2025 | marketbeat.com

Ritholtz Wealth Management Purchases New Position in Premier, Inc. (NASDAQ:PINC)

June 18, 2025 | marketbeat.com

1 Small-Cap Stock to Research Further and 2 to Keep Off Your Radar

June 17, 2025 | msn.com

Premier, Inc. (NASDAQ:PINC) Shares Sold by Rhumbline Advisers

June 14, 2025 | marketbeat.com

Premier African Minerals shares slump 30% after fresh fundraising

June 11, 2025 | proactiveinvestors.co.uk

OLD National Bancorp IN Makes New $234,000 Investment in Premier, Inc. (NASDAQ:PINC)

June 11, 2025 | marketbeat.com

Health-care exec leads 2025 class of CFO of the Year honorees

June 10, 2025 | bizjournals.com

Wedge Capital Management L L P NC Boosts Position in Premier, Inc. (NASDAQ:PINC)

June 10, 2025 | marketbeat.com

42,096 Shares in Premier, Inc. (NASDAQ:PINC) Bought by Two Sigma Investments LP

June 7, 2025 | marketbeat.com

Premier, Inc. (NASDAQ:PINC) Director Sells $26,185.11 in Stock

June 6, 2025 | insidertrades.com

John T. Bigalke Sells 1,137 Shares of Premier, Inc. (NASDAQ:PINC) Stock

June 5, 2025 | marketbeat.com

Insider Selling: Premier, Inc. (NASDAQ:PINC) Director Sells 2,000 Shares of Stock

June 3, 2025 | marketbeat.com

1 Mooning Stock on Our Buy List and 2 to Be Wary Of

June 3, 2025 | msn.com

Premier, Inc. (NASDAQ:PINC) Director Helen M. Boudreau Sells 2,000 Shares

June 3, 2025 | insidertrades.com

Universal Beteiligungs und Servicegesellschaft mbH Makes New $4.29 Million Investment in Premier, Inc. (NASDAQ:PINC)

June 2, 2025 | marketbeat.com

Premier, Inc. (NASDAQ:PINC) Receives Average Rating of "Hold" from Brokerages

June 2, 2025 | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Grows Stock Holdings in Premier, Inc. (NASDAQ:PINC)

June 1, 2025 | marketbeat.com

Nuveen Asset Management LLC Sells 21,079 Shares of Premier, Inc. (NASDAQ:PINC)

June 1, 2025 | marketbeat.com

Premier American Uranium Positioned for U.S. Nuclear Resurgence Amid Transformational Policy Shift

May 27, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PINC, ENOV, GKOS, and AMED Company Descriptions

Amedisys NASDAQ:AMED

$98.08 +0.43 (+0.44%)

Closing price 04:00 PM Eastern

Extended Trading

$98.05 -0.03 (-0.03%)

As of 07:49 PM Eastern

Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care, and palliative care to patients in their homes. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.

Enovis NYSE:ENOV

$32.17 +0.21 (+0.66%)

Closing price 03:59 PM Eastern

Extended Trading

$32.14 -0.04 (-0.11%)

As of 04:32 PM Eastern

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.

Glaukos NYSE:GKOS

$99.42 -0.78 (-0.78%)

Closing price 03:59 PM Eastern

Extended Trading

$99.32 -0.11 (-0.11%)

As of 04:20 PM Eastern

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Premier NASDAQ:PINC

$21.85 +0.10 (+0.46%)

Closing price 04:00 PM Eastern

Extended Trading

$21.86 +0.00 (+0.02%)

As of 04:04 PM Eastern

Premier, Inc., together with its subsidiaries, operates as a healthcare improvement company in the United States. It operates in two segments, Supply Chain Services and Performance Services. The Supply Chain Services segment offers its members with an access to a range of products and services, including medical and surgical products, pharmaceuticals, laboratory supplies, capital equipment, information technology, facilities and construction, and food and nutritional products, as well as purchased services, such as clinical engineering and workforce solutions. This segment also provides the ASCENDrive programs for members to receive group purchasing programs, tiers, and prices; SURPASS Performance Group services; and STOCKD, an e-commerce platform, as well as direct sourcing business; SaaS informatics products; supply chain co-management services; purchased services contracts; direct sourcing solutions; and supply chain resiliency programs. The Performance Services segment provides technology and services platform with offerings that help optimize performance in three main areas, including clinical intelligence, margin improvement, and value-based care under the PINC AI brand; third party administrator services and management of health benefit programs under the Contigo Health brand; and digital invoicing and payables services that offers financial support services to healthcare product suppliers and service providers under the Remitra brand. The company was incorporated in 2013 and is based in Charlotte, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time